Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 57Carcinoma, Non-Small-Cell Lung 34Urinary Bladder Neoplasms 31Neoplasm Metastasis 20Lung Neoplasms 19Ovarian Neoplasms 18Lymphoma, Large B-Cell, Diffuse 18Cholangiocarcinoma 15Biliary Tract Neoplasms 14Triple Negative Breast Neoplasms 13Neoplasms 13Nasopharyngeal Carcinoma 13Colorectal Neoplasms 12Breast Neoplasms 12Carcinoma, Transitional Cell 11Non-Muscle Invasive Bladder Neoplasms 10Recurrence 9Fallopian Tube Neoplasms 9Gallbladder Neoplasms 8Sarcoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Bile Duct Neoplasms 6Uterine Cervical Neoplasms 5Osteosarcoma 5Lymphoma, Non-Hodgkin 5Lymphoma 5Endometrial Neoplasms 5Melanoma 4Hodgkin Disease 4Colonic Neoplasms 4

Interventions

Carboplatin 3durvalumab 2Tretinoin 2Paclitaxel 2Irinotecan 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1tegafur-gimeracil-oteracil 1talazoparib 1sarilumab 1pexidartinib 1pertuzumab 1pembrolizumab 1patritumab 1olaparib 1niraparib 1neratinib 1ganitumab 1dostarlimab 1cemiplimab 1abemaciclib 1Trastuzumab 1Surgical Procedures, Operative 1Standard of Care 1STA 9090 1SGN-LIV1A 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × Gemcitabine × 90 days × Clear all
NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡